Chesapeake Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Chesapeake Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12K	Hold	3,265	–	–	0.01%	229
2026 Q1	$10K	Hold	3,265	–	–	0.01%	237
2025 Q4	$13.4K	Hold	3,265	–	–	0.01%	228
2025 Q3	$15.9K	Buy	3,265 +1,000	+44%	+$5.25K	0.01%	201
2025 Q2	$11.5K	Hold	2,265	–	–	0.01%	202
2025 Q1	$12K	Sell	2,265 -1,272	-36%	-$9.27K	0.01%	191
2024 Q4	$23.9K	Buy	+3,537	New	+$23.8K	0.02%	158

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Chesapeake Asset Management's RXRX Position: Q2 2026 in Review

Chesapeake Asset Management held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 3,265 shares worth $12K. The position accounts for 0.01% of the portfolio, ranked #229.

Chesapeake Asset Management first reported a position in RXRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $23.9K in Q4 2024. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Chesapeake Asset Management held 3,265 shares of Recursion Pharmaceuticals worth $12K as of Q2 2026.
Chesapeake Asset Management left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
Recursion Pharmaceuticals made up 0.01% of Chesapeake Asset Management's portfolio in Q2 2026, its #229 holding.
Chesapeake Asset Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Chesapeake Asset Management's Recursion Pharmaceuticals position peaked at $23.9K in Q4 2024.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Chesapeake Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.